Theravance Biopharma sets Sept. 18 vote on $17.00-a-share Zymeworks merger

What happened

Theravance Biopharma, Inc. (Nasdaq: TBPH) filed a definitive proxy statement on August 21, 2026 asking shareholders to approve its acquisition by Zymeworks Inc. at an extraordinary general meeting scheduled for September 18, 2026 at 1:30 p.m. Pacific Time at the company's offices in South San Francisco.

Theravance is a biopharmaceutical company; the filing lists its standard industrial classification as pharmaceutical preparations. Its shares closed at $17.06 on the day the proxy was filed, down 0.12% from $17.08 the previous close, according to the price data.

The merger agreement was signed on June 28, 2026, according to the proxy. Under its terms, Zymeworks Merger Sub 1 — a Cayman Islands entity wholly owned by Zymeworks — will merge into Theravance, with Theravance surviving as a wholly owned subsidiary of Zymeworks.

Shareholders are being asked to vote on three proposals: the merger itself (Proposal No. 1, a special resolution), the advisory vote on merger-related executive compensation known as golden parachute compensation (Proposal No. 2), and, if needed, an adjournment of the meeting to gather more votes (Proposal No. 3). The board unanimously recommends voting for all three.

The merger must be approved by holders of at least two-thirds of the ordinary shares present in person or by proxy and voting as a single class at the meeting where a quorum is present. The record date for voting was July 31, 2026, and proxy cards must be lodged by 11:59 p.m. Pacific Time on September 17, 2026, the day before the meeting.

What shareholders would receive

At the effective time of the merger, each outstanding Theravance ordinary share converts into the right to receive $17.00 in cash, without interest and less applicable withholding taxes, plus one non-tradable contingent value right, or CVR.

The CVR is not a share and cannot be bought or sold. It is a contractual right to receive future payments tied to ampreloxetine, a Theravance drug candidate, if certain events occur within ten years of the merger's completion. The proxy breaks the CVR into three parts: a pro rata share of 80% of net proceeds from any license, divestiture or other monetization of ampreloxetine; a pro rata share of $50 million in cash on the first commercial sale of the drug in the U.S., UK, Spain, France, Germany or Italy; and a pro rata share of 10% of net sales, on a country-by-country basis, from first commercial sale until the later of the tenth anniversary of that sale, patent expiration or loss of exclusivity.

The proxy states plainly that the CVRs and any payment under them are highly speculative and subject to factors outside Zymeworks' control, and that there is no assurance any triggering transaction will occur or that any CVR payment will ever be made.

A Cayman merger, and dissenters' rights

Theravance is incorporated in the Cayman Islands, and the transaction is structured as a Cayman statutory merger under the Companies Act (As Revised). That is why the deal mechanics in the proxy look unusual to U.S. readers: the filing also asks shareholders to approve an increase in the surviving company's authorized share capital, from $2,002.30 divided into 200,000,000 ordinary shares of $0.00001 par value and 230,000 preferred shares, to $50,000 divided into 50,000 ordinary shares of $1.00 par value.

Cayman law also gives registered holders a dissenters' rights procedure under Section 238 of the Companies Act. A holder who wants to use it must deliver a written objection to the company before the vote on the merger is taken, then follow the statutory steps, and a Cayman court would determine the fair value of the shares. The proxy notes that this court-determined value could be more than, the same as, or less than the $17.00 merger consideration, and warns that failing to precisely follow the procedure can forfeit the right.

What this means

A proxy statement is the document a public company must send shareholders before a vote at a shareholder meeting. It is filed with the SEC on Schedule 14A. The first version, which can still be changed, is a preliminary proxy (PRE 14A); the definitive proxy (DEF 14A) is the final version that can be mailed and voted on. The 'M' in DEFM14A stands for merger — it is the definitive proxy for a merger vote, and it must contain the merger agreement, the plan of merger and the other annexes shareholders are being asked to approve.

A special resolution is a higher voting bar than an ordinary resolution. Here it requires two-thirds of the shares voting, not a simple majority, which is why the deal cannot close on a narrow margin. The advisory compensation vote, by contrast, is an ordinary resolution and is non-binding — it expresses shareholder opinion on the payments executives would receive on a change of control, commonly called golden parachute compensation, without blocking the deal. The adjournment proposal is a procedural tool: if enough shares are not represented at the meeting to approve the merger or establish a quorum, the chairperson can delay the meeting and continue soliciting votes.

A CVR is a way to bridge a disagreement about value in a merger. Rather than paying one fixed price, the buyer pays cash now and adds a right to future payments if a specific asset performs. In this case the asset is ampreloxetine, and the proxy makes clear the CVR is a contingent right, not a security that trades.

If the merger closes, the proxy states Theravance will operate as a privately held, wholly owned subsidiary of Zymeworks and its ordinary shares will no longer be listed on the Nasdaq Global Market. The next scheduled step is the September 18 meeting; the proxy does not state any closing date.